JPH09504377A - Hcvレセプター結合を検出するためのアッセイ - Google Patents
Hcvレセプター結合を検出するためのアッセイInfo
- Publication number
- JPH09504377A JPH09504377A JP8507168A JP50716896A JPH09504377A JP H09504377 A JPH09504377 A JP H09504377A JP 8507168 A JP8507168 A JP 8507168A JP 50716896 A JP50716896 A JP 50716896A JP H09504377 A JPH09504377 A JP H09504377A
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- hcv receptor
- binding
- target cells
- binding ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020003175 receptors Proteins 0.000 title claims abstract description 166
- 102000005962 receptors Human genes 0.000 title claims abstract description 166
- 230000027455 binding Effects 0.000 title claims abstract description 162
- 238000003556 assay Methods 0.000 title claims abstract description 43
- 239000003446 ligand Substances 0.000 claims abstract description 91
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 31
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 9
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 claims description 3
- 230000009137 competitive binding Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 238000002649 immunization Methods 0.000 abstract description 4
- 230000003053 immunization Effects 0.000 abstract description 4
- 229940125575 vaccine candidate Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 106
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 101710091045 Envelope protein Proteins 0.000 description 9
- 241000282577 Pan troglodytes Species 0.000 description 9
- 101710188315 Protein X Proteins 0.000 description 9
- 102100021696 Syncytin-1 Human genes 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 241000238631 Hexapoda Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000282579 Pan Species 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
- HOVAGTYPODGVJG-BWSJPXOBSA-N (2r,3s,4s,5s)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-BWSJPXOBSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 241001533590 Junonia Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 235000004031 Viola x wittrockiana Nutrition 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.標的細胞へのHCVレセプター結合リガンドの結合を測定するアッセイであっ て、HCVレセプター標的細胞へのHCVレセプター結合リガンドまたはその競合的結 合アナログの結合を測定する工程を包含する、アッセイ。 2.以下のアッセイ工程を包含する、請求項1に記載のアッセイ: i)HCVレセプター標的細胞と、HCVレセプター結合リガンドの存在について試 験しようとするサンプルとを混合して、任意のHCVレセプター結合リガンドと該H CVレセプター標的細胞とを結合させる工程、 ii)非結合のHCVレセプター結合リガンドを除去する工程 iii)該HCVレセプター結合リガンドに結合し得る検出可能な抗体と混合して、 結合したHCVレセプター結合リガンドを有する該HCVレセプター標的細胞を標識化 する工程、および iv)該標識化されたHCVレセプター標的細胞の量を検出する工程。 3.以下のアッセイエ程を包含する、請求項1に記載のアッセイ: i)HCVレセプター標的細胞と、HCVレセプター結合リガンドの存在について試 験しようとするサンプルと、限定量のHCVレセプター結合リガンドアナログとを 混合して、該HCVレセプター標的細胞への結合に対して競合させる工程、 ii)非結合のHCVレセプター結合リガンドを除去する工程、 iii)該HCVレセプター結合リガンドに結合し得る検出可能な抗体と混合して、 結合したHCVレセプター結合リガンドを有する該HCVレセプター標的細胞を標識化 する工程、および iv)該HCVレセプター結合リガンドアナログに結合した該HCVレセプター標的細 胞の量を検出する工程。 4.HCVレセプター結合リガンドへの中和抗体の結合から惹起する、HCVレセプタ ー結合リガンドの中和を測定するアッセイであって、以下の工程を包含する、ア ッセイ: i)HCVレセプター標的細胞と、HCVレセプター結合リガンドと、HCV中和抗体の 存在について試験しようとするサンプルとを混合する工程、 ii)非結合のHCVレセプター結合リガンドを除去する工程、 iii)該HCVレセプター結合リガンドに結合し得る検出可能な抗体と混合して、 結合したHCVレセプター結合リガンドを有する該HCVレセプター標的細胞を標識化 する工程、および iv)該HCVレセプター結合リガンドに結合した該HCVレセプター標的細胞の量を 検出する工程。 5.細胞サンプル中のHCVレセプター標的細胞を同定する方法であって、以下の 工程を包含する、方法: i)該細胞サンプルとHCVレセプター結合リガンドとを混合して、任意のHCVレ セプター結合リガンドと該サンプル中の任意のHCVレセプター標的細胞とを結合 させる工程、 ii)非結合のHCVレセプター結合リガンドを除去する工程、 iii)該HCVレセプター結合リガンドに結合し得る検出可能な抗体と混合して、 結合したHCVレセプター結合リガンドを有する該HCVレセプター標的細胞を標識化 する工程、および iv)該標識化されたHCVレセプター標的細胞の量を検出する工程。 6.前記HCVレセプター結合リガンドに結合した前記HCVレセプター標的細胞の量 が、フローサイトメトリーにより検出される、前記請求項のいずれか1つに記載 のアッセイまたは方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9416671A GB9416671D0 (en) | 1994-08-17 | 1994-08-17 | Assay |
GB9416671.7 | 1994-08-17 | ||
PCT/IB1995/000692 WO1996005513A1 (en) | 1994-08-17 | 1995-08-17 | Assay to detect hcv receptor binding |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003272097A Division JP4117230B2 (ja) | 1994-08-17 | 2003-07-08 | Hcvレセプター結合を検出するためのアッセイ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504377A true JPH09504377A (ja) | 1997-04-28 |
JP3629546B2 JP3629546B2 (ja) | 2005-03-16 |
Family
ID=10760012
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50716896A Expired - Lifetime JP3629546B2 (ja) | 1994-08-17 | 1995-08-17 | Hcvレセプター結合を検出するためのアッセイ |
JP2003272097A Expired - Lifetime JP4117230B2 (ja) | 1994-08-17 | 2003-07-08 | Hcvレセプター結合を検出するためのアッセイ |
JP2005342960A Expired - Fee Related JP3886518B2 (ja) | 1994-08-17 | 2005-11-28 | Hcvレセプター結合を検出するためのアッセイ |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003272097A Expired - Lifetime JP4117230B2 (ja) | 1994-08-17 | 2003-07-08 | Hcvレセプター結合を検出するためのアッセイ |
JP2005342960A Expired - Fee Related JP3886518B2 (ja) | 1994-08-17 | 2005-11-28 | Hcvレセプター結合を検出するためのアッセイ |
Country Status (9)
Country | Link |
---|---|
US (3) | US20070298410A1 (ja) |
EP (1) | EP0723665B2 (ja) |
JP (3) | JP3629546B2 (ja) |
AT (1) | ATE258687T1 (ja) |
AU (1) | AU3189495A (ja) |
CA (1) | CA2174212C (ja) |
DE (1) | DE69532498T3 (ja) |
GB (1) | GB9416671D0 (ja) |
WO (1) | WO1996005513A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9517926D0 (en) | 1995-09-01 | 1995-11-01 | Biocine Spa | Binding protein |
ES2334727T3 (es) | 1997-10-06 | 2010-03-15 | Novartis Vaccines And Diagnostics S.R.L. | Proteina receptora cd81 de la hepatitis c. |
GB9927320D0 (en) | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
DK1233782T3 (da) | 1999-12-01 | 2009-02-09 | Novartis Vaccines & Diagnostic | Fremkaldelse af HCV-specifikke antistoffer |
AU2005295317B2 (en) * | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
WO2007111964A2 (en) * | 2006-03-22 | 2007-10-04 | Genimmune N.V. | Hepatitis c virus neutralizing antibodies |
EP2945528A1 (en) * | 2013-01-17 | 2015-11-25 | Koninklijke Philips N.V. | A system and method for influence an operation of a device of the system |
CN116930475A (zh) * | 2022-03-31 | 2023-10-24 | 上海细胞治疗集团药物技术有限公司 | 中和抗体检测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0493745A1 (en) * | 1990-12-21 | 1992-07-08 | Dojindo Laboratories | Fluorescent compound, complex, reagent, and specific binding assay employing said reagent |
GB9517926D0 (en) * | 1995-09-01 | 1995-11-01 | Biocine Spa | Binding protein |
-
1994
- 1994-08-17 GB GB9416671A patent/GB9416671D0/en active Pending
-
1995
- 1995-08-17 AT AT95927918T patent/ATE258687T1/de active
- 1995-08-17 CA CA002174212A patent/CA2174212C/en not_active Expired - Lifetime
- 1995-08-17 JP JP50716896A patent/JP3629546B2/ja not_active Expired - Lifetime
- 1995-08-17 DE DE69532498T patent/DE69532498T3/de not_active Expired - Lifetime
- 1995-08-17 EP EP95927918A patent/EP0723665B2/en not_active Expired - Lifetime
- 1995-08-17 AU AU31894/95A patent/AU3189495A/en not_active Abandoned
- 1995-08-17 WO PCT/IB1995/000692 patent/WO1996005513A1/en active IP Right Grant
-
2003
- 2003-07-08 JP JP2003272097A patent/JP4117230B2/ja not_active Expired - Lifetime
-
2005
- 2005-11-28 JP JP2005342960A patent/JP3886518B2/ja not_active Expired - Fee Related
-
2007
- 2007-04-06 US US11/784,521 patent/US20070298410A1/en not_active Abandoned
-
2008
- 2008-03-18 US US12/077,367 patent/US20080176219A1/en not_active Abandoned
-
2009
- 2009-10-05 US US12/587,308 patent/US20100203501A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB9416671D0 (en) | 1994-10-12 |
EP0723665B1 (en) | 2004-01-28 |
US20070298410A1 (en) | 2007-12-27 |
JP2006133233A (ja) | 2006-05-25 |
US20100203501A1 (en) | 2010-08-12 |
WO1996005513A1 (en) | 1996-02-22 |
CA2174212C (en) | 2003-10-28 |
ATE258687T1 (de) | 2004-02-15 |
EP0723665B2 (en) | 2008-01-02 |
DE69532498T3 (de) | 2008-11-13 |
JP3886518B2 (ja) | 2007-02-28 |
CA2174212A1 (en) | 1996-02-22 |
DE69532498T2 (de) | 2004-12-02 |
AU3189495A (en) | 1996-03-07 |
JP3629546B2 (ja) | 2005-03-16 |
JP2004004113A (ja) | 2004-01-08 |
US20080176219A1 (en) | 2008-07-24 |
EP0723665A1 (en) | 1996-07-31 |
DE69532498D1 (de) | 2004-03-04 |
JP4117230B2 (ja) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7384785B2 (en) | Diagnostic test for West Nile virus | |
KR100847586B1 (ko) | C형 간염 바이러스의 측정방법 | |
JP3510232B2 (ja) | ウイルスの検出又は測定方法 | |
JP3886518B2 (ja) | Hcvレセプター結合を検出するためのアッセイ | |
Ying et al. | Urine is a viral antigen reservoir in hepatitis E virus infection | |
US7320875B2 (en) | Hepatitis C virus E2 binding protein | |
JPH0940694A (ja) | 肝炎gbウイルスの合成ペプチド及びその使用 | |
Adhikari et al. | Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection | |
WO2021219029A1 (en) | Sars-cov-2 viral proteins and use thereof | |
JP3176570B2 (ja) | Hcvの検出又は測定方法 | |
JPH10506382A (ja) | 急性および慢性c型肝炎ウイルス感染の鑑別診断のための方法および組成物 | |
CN104119436B (zh) | 抗丙型肝炎病毒的中和性全人单克隆抗体 | |
RU2439080C2 (ru) | Биоанализ и пептиды, используемые в нем | |
Infantolino et al. | Localization of hepatitis C virus antigen (s) by immunohistochemistry on fixed-embedded liver tissue | |
CN116990507A (zh) | 一种用于猴痘病毒感染的早期筛查的方法 | |
JP2001224371A (ja) | Hcvの検出又は測定方法 | |
NZ224742A (en) | Hiv assay involving detection of antibodies against f protein or peptides derived from this protein | |
CN114751980A (zh) | 一种用于新冠抗原检测的单抗阻断剂 | |
JP2012526088A (ja) | 自己免疫疾患を検出するためのバイオマーカー抗体と診断装置 | |
Pillot et al. | ELISA in serodiagnosis of HCV infection | |
JPH06317597A (ja) | C型肝炎ウイルスのグルーピング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040621 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041026 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041119 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041117 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071224 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081224 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091224 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101224 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101224 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111224 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111224 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121224 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121224 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131224 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |